Compugen Ltd (CGEN)

$1.80 +0.13 (7.78%)
Market Cap 149.03M
Revenue (ttm) 27.86M
Net Income (ttm) -14.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -51.08%
Debt to Equity Ratio 0.00
Volume 333,400
Avg Vol 410,678
Day's Range N/A - N/A
Shares Out 89.24M
Stochastic %K 27%
Beta 2.61
Analysts Strong Sell
Price Target $6.25

Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of P...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 765 8585
Fax: 972 3 765 8555
Website: cgen.com
Address:
Azrieli Center, Building D 26 Harokmim Street, Holon, Israel
Urik
Urik Oct. 25 at 5:39 PM
$CGEN great technical setup 🔝🔝
0 · Reply
TwitteringTom
TwitteringTom Oct. 24 at 7:34 PM
$CGEN what we got a fake news friday pop
0 · Reply
LarryYMB
LarryYMB Oct. 24 at 1:27 PM
$CGEN my new avadel got up to 30k shares, lets go!
2 · Reply
TwitteringTom
TwitteringTom Oct. 22 at 4:45 PM
$CGEN Oh man all that ESMO data was be hitting the market...LOL.... i just do not get why this wont move
1 · Reply
Ghrr
Ghrr Oct. 22 at 4:12 PM
$CGEN This stock should be well north of $2. I have faith thst it will get to $5 but not sure it will be in my lifetime...lol
0 · Reply
Otus
Otus Oct. 21 at 1:58 PM
$CGEN we went from a piece dividend to a piece of poo in a blink.
2 · Reply
TwitteringTom
TwitteringTom Oct. 21 at 1:56 PM
$CGEN that was fun for the minute lol
0 · Reply
HuntingBenjmins
HuntingBenjmins Oct. 21 at 2:57 AM
$CGEN I’d expect a good run here once that ESMO data sinks in.
0 · Reply
TwitteringTom
TwitteringTom Oct. 14 at 7:54 PM
$CGEN this volume and pricing going to disappear in a few sessions>
0 · Reply
TwitteringTom
TwitteringTom Oct. 14 at 3:43 PM
$CGEN wellll that was somewhat fun
0 · Reply
Latest News on CGEN
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

Oct 13, 2025, 7:00 AM EDT - 12 days ago

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

Compugen to Present at SITC 2025

Oct 6, 2025, 7:00 AM EDT - 19 days ago

Compugen to Present at SITC 2025

Compugen to Present Research at the Single Cell Genomics 2025 Conference

Sep 8, 2025, 7:00 AM EDT - 6 weeks ago

Compugen to Present Research at the Single Cell Genomics 2025 Conference

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 7:00 AM EDT - 2 months ago

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients

Aug 8, 2025, 5:13 AM EDT - 2 months ago

Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients

Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 6:30 AM EDT - 2 months ago

Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript

Compugen Reports Second Quarter 2025 Results

Aug 6, 2025, 7:00 AM EDT - 2 months ago

Compugen Reports Second Quarter 2025 Results

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Jul 28, 2025, 7:00 AM EDT - 3 months ago

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

Jul 23, 2025, 7:00 AM EDT - 3 months ago

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Jul 21, 2025, 7:00 AM EDT - 3 months ago

Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

Jun 12, 2025, 7:00 AM EDT - 4 months ago

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript

May 19, 2025, 10:21 AM EDT - 5 months ago

Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript

Compugen Reports First Quarter 2025 Results

May 19, 2025, 7:00 AM EDT - 5 months ago

Compugen Reports First Quarter 2025 Results

Compugen Announces Leadership Transitions Effective September 2025

May 13, 2025, 7:00 AM EDT - 5 months ago

Compugen Announces Leadership Transitions Effective September 2025

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

May 5, 2025, 7:00 AM EDT - 6 months ago

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Mar 26, 2025, 7:00 AM EDT - 7 months ago

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 10:34 AM EST - 8 months ago

Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript

Compugen Reports Fourth Quarter and Full Year 2024 Results

Mar 4, 2025, 7:00 AM EST - 8 months ago

Compugen Reports Fourth Quarter and Full Year 2024 Results

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Mar 3, 2025, 7:00 AM EST - 8 months ago

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Feb 26, 2025, 7:00 AM EST - 8 months ago

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 18, 2025, 7:00 AM EST - 8 months ago

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Compugen: Immuno-Oncology Innovator Poised For A Comeback

Feb 18, 2025, 6:11 AM EST - 8 months ago

Compugen: Immuno-Oncology Innovator Poised For A Comeback

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 9 months ago

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Jan 8, 2025, 7:00 AM EST - 10 months ago

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Nov 27, 2024, 7:00 AM EST - 11 months ago

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 3:35 PM EST - 1 year ago

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript

Compugen Reports Third Quarter 2024 Results

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compugen Reports Third Quarter 2024 Results

Compugen to Participate in Stifel 2024 Healthcare Conference

Nov 11, 2024, 7:00 AM EST - 1 year ago

Compugen to Participate in Stifel 2024 Healthcare Conference

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Compugen to Present New Clinical Data at SITC 2024

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data at SITC 2024

Compugen to Present at Single Cell Genomics 2024 Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Single Cell Genomics 2024 Conference

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 5:54 AM EDT - 1 year ago

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript

Compugen Reports Second Quarter 2024 Results

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports Second Quarter 2024 Results

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Compugen to Present at Upcoming Antibody Industrial Symposium

Jun 17, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Upcoming Antibody Industrial Symposium

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

May 30, 2024, 7:00 AM EDT - 1 year ago

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AZN

Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript

May 20, 2024, 12:22 PM EDT - 1 year ago

Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript

Compugen Reports First Quarter 2024 Results

May 20, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports First Quarter 2024 Results

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

May 16, 2024, 7:00 AM EDT - 1 year ago

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

Compugen Appoints David Silberman as Chief Financial Officer

May 15, 2024, 7:00 AM EDT - 1 year ago

Compugen Appoints David Silberman as Chief Financial Officer

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

May 6, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

Compugen to Participate in Two Upcoming Investor Conferences

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Compugen to Participate in Two Upcoming Investor Conferences

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

Mar 6, 2024, 7:00 AM EST - 1 year ago

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 2:41 PM EST - 1 year ago

Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript

Urik
Urik Oct. 25 at 5:39 PM
$CGEN great technical setup 🔝🔝
0 · Reply
TwitteringTom
TwitteringTom Oct. 24 at 7:34 PM
$CGEN what we got a fake news friday pop
0 · Reply
LarryYMB
LarryYMB Oct. 24 at 1:27 PM
$CGEN my new avadel got up to 30k shares, lets go!
2 · Reply
TwitteringTom
TwitteringTom Oct. 22 at 4:45 PM
$CGEN Oh man all that ESMO data was be hitting the market...LOL.... i just do not get why this wont move
1 · Reply
Ghrr
Ghrr Oct. 22 at 4:12 PM
$CGEN This stock should be well north of $2. I have faith thst it will get to $5 but not sure it will be in my lifetime...lol
0 · Reply
Otus
Otus Oct. 21 at 1:58 PM
$CGEN we went from a piece dividend to a piece of poo in a blink.
2 · Reply
TwitteringTom
TwitteringTom Oct. 21 at 1:56 PM
$CGEN that was fun for the minute lol
0 · Reply
HuntingBenjmins
HuntingBenjmins Oct. 21 at 2:57 AM
$CGEN I’d expect a good run here once that ESMO data sinks in.
0 · Reply
TwitteringTom
TwitteringTom Oct. 14 at 7:54 PM
$CGEN this volume and pricing going to disappear in a few sessions>
0 · Reply
TwitteringTom
TwitteringTom Oct. 14 at 3:43 PM
$CGEN wellll that was somewhat fun
0 · Reply
Albbro
Albbro Oct. 13 at 9:35 PM
$CGEN to what do we owe this jump today?
2 · Reply
HuntingBenjmins
HuntingBenjmins Oct. 13 at 6:34 PM
$CGEN wow nice!
2 · Reply
_www_larval_com_
_www_larval_com_ Oct. 13 at 6:28 PM
$CGEN just popped 6% higher to 27% (~876Kv) a moment ago, 10/17 options, follow for more volatility.
0 · Reply
DARKP00L
DARKP00L Oct. 13 at 4:46 PM
$CGEN the market is buzzing about this stock. Expect possible price changes!
0 · Reply
HuntingBenjmins
HuntingBenjmins Oct. 13 at 4:17 PM
$CGEN My buys @ $1.30 last month looking great right now.
0 · Reply
HuntingBenjmins
HuntingBenjmins Oct. 13 at 2:25 PM
$CGEN ESMO Abstract. https://cgen.com/wp-content/uploads/Yeku_O_et_al_ESMO_2025_COM701_Pooled_Phase_1_analysis_ABSTRACT.pdf
0 · Reply
HebrewHAMmer87
HebrewHAMmer87 Oct. 13 at 1:18 PM
$CGEN 2.50 real soon
0 · Reply
DARKP00L
DARKP00L Oct. 13 at 11:11 AM
$CGEN 07:10 on Oct. 13 2025 Compugen Publishes Pooled Data Showing COM701 Activity in Platinum-Resistant Ovarian Cancer Ahead of ESMO Presentation #tradeideas
0 · Reply
HuntingBenjmins
HuntingBenjmins Oct. 13 at 3:47 AM
$CGEN RCUS showing what TIGIT can do. I’m guessing we’re next.
0 · Reply
Otus
Otus Oct. 10 at 4:15 PM
$CGEN I’m thinking this recent move is a peace dividend.
2 · Reply
wenmoon_stonks
wenmoon_stonks Oct. 10 at 2:07 PM
$CGEN oh, hello
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 9 at 10:56 PM
9/26/25 list results $CGAU $CGEN $CGNX $CGON 🔥 Cycle Trading Signal plugged into AI 🔥 list
0 · Reply